Sanofi (France) (SAN.PA) Deal Could Net Selecta Biosciences, Inc. $900 Million
11/28/2012 6:42:44 AM
More...
|
Selecta Biosciences, Inc. Receives 2012 Edison Award’s Gold Medal for Best Pharmaceutical Product Innovation
5/9/2012 10:27:33 AM
More...
|
Selecta Biosciences, Inc. Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention
11/21/2011 8:36:09 AM
More...
|
Selecta Biosciences, Inc. Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies
10/27/2011 6:47:14 AM
More...
|
Selecta Biosciences, Inc. Appoints Takashi Kei Kishimoto, Ph.D., as Chief Scientific Officer
8/31/2011 9:21:51 AM
More...
|
Selecta Biosciences, Inc. Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria
8/31/2011 9:15:30 AM
More...
|
The Juvenile Diabetes Research Foundation and Selecta Biosciences, Inc. Enter Research Collaboration for Vaccines for Type 1 Diabetes
6/9/2011 9:40:41 AM
More...
|
Selecta Biosciences, Inc. Appoints Peter Keller as Vice President of Business Development and Alliance Management
6/9/2011 9:21:32 AM
More...
|
Selecta Biosciences, Inc. Receives $3 Million from National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) to Develop Nicotine Vaccine for Smoking Cessation
8/16/2010 8:03:58 AM
More...
|
Former Solvay Pharmaceuticals, Inc. Chief Werner Cautreels, Ph.D. Takes Lead Role at Startup Selecta Biosciences, Inc.
8/16/2010 6:52:29 AM
More...
|
|